The SeQuent™™ Please drug-coated balloon system for percutaneous transluminal coronary angioplasty. (April 2011)

• Record Type: Journal Article
• Authors: Schmitmeier, Stephanie; Cremers, Bodo; Clever, Yvonne P; Speck, Ulrich; Scheller, Bruno
• Is Part Of: Interventional cardiology. Volume 3:Number 2(2011)
• Page Start: 133
• Page End: 147
• Publication Date: 2011-04
• Subjects: coronary artery disease -- drug-coated balloon -- paclitaxel -- percutaneous coronary intervention; Cardiology -- Periodicals; Coronary heart disease -- Treatment -- Periodicals; 616.1205
• DOI: 10.2217/ica.11.10
• Languages: English
• ISSNs: 1755-5310

Abstract

Endovascular therapy for treatment of arterial obstructions has emerged as one of the most promising techniques in minimally invasive medicine during the last few decades. However, long-term outcome remains an area of concern in many applications. Drug-coated balloons represent an enhancement of the therapeutic repertoire for the interventional cardiologists. Among drug-coated balloons currently available on the market is the the SeQuent™™ Please device, a coronary balloon catheter that combines balloon angioplasty with local delivery of paclitaxel. In several small, but randomized, clinical trials, the paclitaxel-coated SeQuent Please balloon catheter system has been shown to be safe and effective in reducing restenosis in patients with coronary in-stent restenosis, indicating that restenosis inhibition by immediate drug release is feasible. This article reviews the rationale for the use of paclitaxel-coated balloons, along with a focus on the SeQuent Please with its concept and the currently available clinical data on its use in diseased coronary arteries.